331 related articles for article (PubMed ID: 25283354)
1. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
Procopio G; Pusceddu S; Buzzoni R
Tumori; 2012; 98(3):394. PubMed ID: 22825518
[No Abstract] [Full Text] [Related]
3. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Papaetis GS; Syrigos KN
BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.
Vázquez S; León L; Fernández O; Lázaro M; Grande E; Aparicio L
Adv Ther; 2012 Mar; 29(3):202-17. PubMed ID: 22328304
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
7. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
Theou-Anton N; Faivre S; Dreyer C; Raymond E
Drug Saf; 2009; 32(9):717-34. PubMed ID: 19670913
[TBL] [Abstract][Full Text] [Related]
8. Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
Lin LZ; Li P; Chen HR; Pang LJ
Future Oncol; 2013 Jun; 9(6):909-13. PubMed ID: 23718311
[TBL] [Abstract][Full Text] [Related]
10. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
Blumenthal GM; Cortazar P; Zhang JJ; Tang S; Sridhara R; Murgo A; Justice R; Pazdur R
Oncologist; 2012; 17(8):1108-13. PubMed ID: 22836448
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour.
Shea YF; Chiu WY; Mok MY; Hung IF; Yau CC
J Clin Pharm Ther; 2013 Aug; 38(4):327-9. PubMed ID: 23586819
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
13. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment.
Fountas A; Tigas S; Giotaki Z; Petrakis D; Pentheroudakis G; Tsatsoulis A
Hormones (Athens); 2015; 14(3):438-41. PubMed ID: 25553766
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Matsumoto K; Sawaki A; Mizuno N; Hara K; Hijioka S; Niwa Y; Tajika M; Kawai H; Kondo S; Yamao K
Jpn J Clin Oncol; 2011 Jan; 41(1):57-62. PubMed ID: 20858619
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
16. Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.
Grande E; José Díez J; Pachón V; Angeles Vaz M; Longo F; Guillén C; García de Paredes ML; Carrato A
Anticancer Drugs; 2011 Jun; 22(5):477-9. PubMed ID: 21346550
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
Bisht S; Feldmann G; Brossart P
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
Motzer RJ; Escudier B; Gannon A; Figlin RA
Oncologist; 2017 Jan; 22(1):41-52. PubMed ID: 27807302
[TBL] [Abstract][Full Text] [Related]
20. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Capdevila J; Tabernero J
Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
